Taken together, these findings indicate that activation of CB2 and/or PPARγ as well as antagonism of CB1 and/or A2A adenosine receptors may become potent tools in the management of SSc and maybe in other fibrotic diseases as well. This evidence concerns the gene PPARG and systemic sclerosis.